Covered recipient · General Payments record
BRENDA MC LATOWSKY
Allopathic & Osteopathic Physicians Dermatology Procedural Dermatology
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2023 · Entire year
$23,178.11
100 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2023 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Consulting Fee | $15,136.25 | 6 |
| Food and Beverage | $4,045.52 | 68 |
| Travel and Lodging | $2,673.29 | 11 |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $1,255.80 | 9 |
| Education | $67.25 | 6 |
By paying entity
PY2023 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| ABBVIE INC. | $16,759.60 | 46 |
| Merz North America, Inc. | $3,816.01 | 17 |
| STRATA Skin Sciences, Inc. | $1,400.00 | 1 |
| Allergan, Inc. | $277.90 | 1 |
| Amgen Inc. | $220.57 | 3 |
| Galderma Laboratories, L.P. | $133.59 | 6 |
| Dermavant Sciences, Inc. | $93.84 | 5 |
| E.R. Squibb & Sons, L.L.C. | $60.27 | 3 |
| Regeneron Healthcare Solutions, Inc. | $58.81 | 2 |
| Janssen Biotech, Inc. | $44.83 | 2 |
| Incyte Corporation | $44.45 | 2 |
| Sun Pharmaceutical Industries Inc. | $39.99 | 2 |
| GENZYME CORPORATION | $38.97 | 2 |
| PFIZER INC. | $38.17 | 2 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $28.97 | 1 |
| Lilly USA, LLC | $27.63 | 1 |
| LEO Pharma Inc. | $25.00 | 1 |
| MAYNE PHARMA COMMERCIAL LLC | $24.48 | 1 |
| Arcutis Biotherapeutics, Inc. | $22.86 | 1 |
| Axonics, Inc. | $22.17 | 1 |
Page 2 of 2; records 51–100 of 100 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
BRENDA MC LATOWSKY
NPI 1306010467 · CMS profile ID 13863
Allopathic & Osteopathic Physicians / Dermatology / Procedural Dermatology
SCOTTSDALE, AZ
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 2 of 2; records 51–100 of 100 matching records. This page contains 50 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1306010467?year=2023&recipient=provider&page=2#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- BRENDA MC LATOWSKY, NPI 1306010467, CMS profile ID 13863. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–100 of 100 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1306010467?year=2023&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
- APA 7
- IndustryPayments. (2026). BRENDA MC LATOWSKY, NPI 1306010467, CMS profile ID 13863. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–100 of 100 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1306010467?year=2023&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
- Bluebook
- BRENDA MC LATOWSKY, NPI 1306010467, CMS profile ID 13863, IndustryPayments, General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 2; records 51–100 of 100 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9. https://industrypayments.org/provider/npi-1306010467?year=2023&recipient=provider&page=2#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2023
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2023 · Physicians and non-physician practitioners · CMS publication 2026-06-30
100 matching records · $23,178.11 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 51–100 of 100.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| ABBVIE INC. | $378.00 | 08/25/2023 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 997730581 | CMS |
| Dermavant Sciences, Inc. | $15.68 | 08/19/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 991215491 | CMS |
| ABBVIE INC. | $1,278.00 | 08/18/2023 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 997730579 | CMS |
| E.R. Squibb & Sons, L.L.C. | $19.73 | 08/11/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1016420011 | CMS |
| ABBVIE INC. | $50.20 | 08/10/2023 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 997730577 | CMS |
| ABBVIE INC. | $28.36 | 08/07/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1087521972 | CMS |
| ABBVIE INC. | $8.45 | 07/18/2023 | Education | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 997730575 | CMS |
| Janssen Biotech, Inc. | $21.88 | 07/14/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 988024657 | CMS |
| Axonics, Inc. | $22.17 | 07/13/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1051809025 | CMS |
| ABBVIE INC. | $102.16 | 06/26/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 997730573 | CMS |
| Galderma Laboratories, L.P. | $6.17 | 06/26/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1059710185 | CMS |
| ABBVIE INC. | $1,860.25 | 06/19/2023 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 997730571 | CMS |
| ABBVIE INC. | $182.30 | 06/15/2023 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 997730569 | CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $28.97 | 06/09/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 996870539 | CMS |
| Galderma Laboratories, L.P. | $15.67 | 05/24/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1059710181 | CMS |
| Merz North America, Inc. | $19.38 | 05/20/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1050997123 | CMS |
| Merz North America, Inc. | $109.21 | 05/20/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1050997127 | CMS |
| Merz North America, Inc. | $42.96 | 05/20/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1050997131 | CMS |
| Merz North America, Inc. | $62.98 | 05/20/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1050997133 | CMS |
| Merz North America, Inc. | $88.56 | 05/20/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1050997137 | CMS |
| MAYNE PHARMA COMMERCIAL LLC | $24.48 | 05/19/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1060912261 | CMS |
| Merz North America, Inc. | $39.42 | 05/19/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1050997121 | CMS |
| Merz North America, Inc. | $135.17 | 05/19/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1050997125 | CMS |
| Merz North America, Inc. | $593.75 | 05/19/2023 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1050997129 | CMS |
| Merz North America, Inc. | $514.76 | 05/19/2023 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1050997135 | CMS |
| Merz North America, Inc. | $190.01 | 05/17/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1050997113 | CMS |
| ABBVIE INC. | $89.00 | 05/12/2023 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 997730567 | CMS |
| ABBVIE INC. | $8.45 | 05/02/2023 | Education | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 997730561 | CMS |
| ABBVIE INC. | $8.45 | 05/02/2023 | Education | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 997730563 | CMS |
| ABBVIE INC. | $8.45 | 05/02/2023 | Education | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 997730565 | CMS |
| ABBVIE INC. | $26.85 | 04/15/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 997730559 | CMS |
| ABBVIE INC. | $88.50 | 04/14/2023 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 997730557 | CMS |
| ABBVIE INC. | $125.55 | 04/13/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 997730555 | CMS |
| STRATA Skin Sciences, Inc. | $1,400.00 | 03/29/2023 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1053061585 | CMS |
| Incyte Corporation | $19.81 | 03/24/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1044917227 | CMS |
| ABBVIE INC. | $890.00 | 03/17/2023 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 997730553 | CMS |
| Merz North America, Inc. | $280.39 | 03/10/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1050997139 | CMS |
| ABBVIE INC. | $86.03 | 03/09/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 997730551 | CMS |
| Dermavant Sciences, Inc. | $24.45 | 03/08/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 991215487 | CMS |
| Merz North America, Inc. | $140.20 | 03/06/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1050997115 | CMS |
| ABBVIE INC. | $132.63 | 02/24/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 997730549 | CMS |
| Incyte Corporation | $24.64 | 02/24/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1044917099 | CMS |
| Amgen Inc. | $99.58 | 02/22/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1020545511 | CMS |
| Arcutis Biotherapeutics, Inc. | $22.86 | 02/15/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1044661741 | CMS |
| Galderma Laboratories, L.P. | $3.10 | 02/13/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1059710179 | CMS |
| ABBVIE INC. | $28.70 | 01/21/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 997730547 | CMS |
| E.R. Squibb & Sons, L.L.C. | $21.42 | 01/13/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1016419863 | CMS |
| Galderma Laboratories, L.P. | $3.75 | 01/13/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1059710175 | CMS |
| Allergan, Inc. | $277.90 | 01/06/2023 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 973113973 | CMS |
| E.R. Squibb & Sons, L.L.C. | $19.12 | 01/03/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1016419859 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Principal investigator | $584,068.28 | 32 |
| PY2024 | Recipient | $1,800.00 | 1 |
| PY2024 | Principal investigator | $107,854.01 | 138 |
| PY2023 | Principal investigator | $275,312.20 | 115 |
| PY2022 | Recipient | $136.00 | 1 |
| PY2022 | Principal investigator | $1,102,786.02 | 70 |
| PY2021 | Recipient | $200.00 | 1 |
| PY2021 | Principal investigator | $335,050.25 | 54 |
| PY2020 | Recipient | $3,549.00 | 1 |
| PY2020 | Principal investigator | $570,904.87 | 79 |
| PY2019 | Recipient | $13,343.75 | 2 |
| PY2019 | Principal investigator | $530,113.82 | 40 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
32 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | ABBVIE INC. | $2,177.82 | 12/31/2025 | Non-covered Recipient Entity INVESTIGATE MD LLC | A Phase 1 Study to Evaluate the Safety and Efficacy of Co-administration of AGN-151586 and BOTOX in Subjects for Treatment of Glabellar Lines (GL) | No dispute reported | 06/30/2026 | 1202534787 |
| Principal investigator 1 | ABBVIE INC. | $2,437.50 | 12/11/2025 | Non-covered Recipient Entity INVESTIGATE MD LLC | A Study to Assess Non-Invasive Subcutaneous Fat Reduction in the Submental, Inner Thigh and Back/Bra Areas With the CoolSculpting Elite System | No dispute reported | 06/30/2026 | 1202529984 |
| Principal investigator 1 | ABBVIE INC. | $28,429.60 | 12/04/2025 | Non-covered Recipient Entity INVESTIGATE MD LLC | A Study to Assess the Adverse Events of Intramuscular Injections of AGN-151586 and OnabotulinumtoxinA in Adult Participants for the Change of Glabellar Lines (GL) | No dispute reported | 06/30/2026 | 1202526586 |
| Principal investigator 1 | ABBVIE INC. | $35,724.00 | 11/17/2025 | Non-covered Recipient Entity INVESTIGATE MD LLC | A Study to Assess Non-Invasive Subcutaneous Fat Reduction in the Submental, Inner Thigh and Back/Bra Areas With the CoolSculpting Elite System | No dispute reported | 06/30/2026 | 1202524435 |
| Principal investigator 1 | Galderma Laboratories, L.P. | $1,800.00 | 11/12/2025 | Non-covered Recipient Entity INVESTIGATE MD LLC | A randomized, evaluator-blinded, parallel group, comparator-controlled, multicenter study to evaluate the safety and effectiveness and safety of GP0112 for cheek augmentation, midface volumization and correction of midface contour deficiencies | No dispute reported | 06/30/2026 | 1234517511 |
| Principal investigator 1 | ABBVIE INC. | $21,740.55 | 11/05/2025 | Non-covered Recipient Entity INVESTIGATE MD LLC | A Study to Assess the Adverse Events of Intramuscular Injections of AGN-151586 and OnabotulinumtoxinA in Adult Participants for the Change of Glabellar Lines (GL) | No dispute reported | 06/30/2026 | 1202521749 |
| Principal investigator 1 | Galderma Laboratories, L.P. | $21,434.05 | 10/17/2025 | Non-covered Recipient Entity INVESTIGATE MD LLC | A randomized, evaluator-blinded, parallel group, comparator-controlled, multicenter study to evaluate the safety and effectiveness and safety of GP0112 for cheek augmentation, midface volumization and correction of midface contour deficiencies | No dispute reported | 06/30/2026 | 1234517318 |
| Principal investigator 1 | ABBVIE INC. | $31,072.80 | 10/09/2025 | Non-covered Recipient Entity INVESTIGATE MD LLC | A Study to Assess the Adverse Events of Intramuscular Injections of AGN-151586 and OnabotulinumtoxinA in Adult Participants for the Change of Glabellar Lines (GL) | No dispute reported | 06/30/2026 | 1202514617 |
| Principal investigator 1 | ABBVIE INC. | $8,879.00 | 10/09/2025 | Non-covered Recipient Entity INVESTIGATE MD LLC | A Study to Assess Non-Invasive Subcutaneous Fat Reduction in the Submental, Inner Thigh and Back/Bra Areas With the CoolSculpting Elite System | No dispute reported | 06/30/2026 | 1202514619 |
| Principal investigator 1 | ABBVIE INC. | $1,536.50 | 10/09/2025 | Non-covered Recipient Entity INVESTIGATE MD LLC | A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1202514621 |
| Principal investigator 1 | ABBVIE INC. | $97,294.50 | 09/04/2025 | Non-covered Recipient Entity INVESTIGATE MD LLC | A Study to Assess the Adverse Events of Intramuscular Injections of AGN-151586 and OnabotulinumtoxinA in Adult Participants for the Change of Glabellar Lines (GL) | No dispute reported | 06/30/2026 | 1202509218 |
| Principal investigator 1 | ABBVIE INC. | $1,536.50 | 09/03/2025 | Non-covered Recipient Entity INVESTIGATE MD LLC | A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1202507827 |
| Principal investigator 1 | ABBVIE INC. | $147,752.55 | 08/06/2025 | Non-covered Recipient Entity INVESTIGATE MD LLC | A Study to Assess the Adverse Events of Intramuscular Injections of AGN-151586 and OnabotulinumtoxinA in Adult Participants for the Change of Glabellar Lines (GL) | No dispute reported | 06/30/2026 | 1202503453 |
| Principal investigator 1 | Galderma Laboratories, L.P. | $180.00 | 08/05/2025 | Non-covered Recipient Entity INVESTIGATE MD LLC | A randomized, evaluator-blinded, parallel group, comparator-controlled, multicenter study to evaluate the safety and effectiveness and safety of GP0112 for cheek augmentation, midface volumization and correction of midface contour deficiencies | No dispute reported | 06/30/2026 | 1234515578 |
| Principal investigator 1 | Galderma Laboratories, L.P. | $1,800.11 | 07/18/2025 | Non-covered Recipient Entity INVESTIGATE MD LLC | A randomized, evaluator-blinded, parallel group, comparator-controlled, multicenter study to evaluate the safety and effectiveness and safety of GP0112 for cheek augmentation, midface volumization and correction of midface contour deficiencies | No dispute reported | 06/30/2026 | 1234515339 |
| Principal investigator 1 | Galderma Laboratories, L.P. | $11,386.12 | 07/09/2025 | Non-covered Recipient Entity INVESTIGATE MD LLC | A randomized, evaluator-blinded, parallel group, comparator-controlled, multicenter study to evaluate the safety and effectiveness and safety of GP0112 for cheek augmentation, midface volumization and correction of midface contour deficiencies | No dispute reported | 06/30/2026 | 1234515282 |
| Principal investigator 1 | ABBVIE INC. | $79,880.55 | 07/08/2025 | Non-covered Recipient Entity INVESTIGATE MD LLC | A Study to Assess the Adverse Events of Intramuscular Injections of AGN-151586 and OnabotulinumtoxinA in Adult Participants for the Change of Glabellar Lines (GL) | No dispute reported | 06/30/2026 | 1202497176 |
| Principal investigator 1 | ABBVIE INC. | $5,000.00 | 07/02/2025 | Non-covered Recipient Entity INVESTIGATE MD LLC | A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) | No dispute reported | 06/30/2026 | 1202494907 |
| Principal investigator 1 | Galderma Laboratories, L.P. | $9,411.70 | 06/20/2025 | Non-covered Recipient Entity INVESTIGATE MD LLC | A randomized, evaluator-blinded, parallel group, comparator-controlled, multicenter study to evaluate the safety and effectiveness and safety of GP0112 for cheek augmentation, midface volumization and correction of midface contour deficiencies | No dispute reported | 06/30/2026 | 1234515059 |
| Principal investigator 1 | Galderma Laboratories, L.P. | $14,400.90 | 06/03/2025 | Non-covered Recipient Entity INVESTIGATE MD LLC | A randomized, evaluator-blinded, parallel group, comparator-controlled, multicenter study to evaluate the safety and effectiveness and safety of GP0112 for cheek augmentation, midface volumization and correction of midface contour deficiencies | No dispute reported | 06/30/2026 | 1234514871 |
| Principal investigator 1 | Galderma Laboratories, L.P. | $12,023.98 | 05/15/2025 | Non-covered Recipient Entity INVESTIGATE MD LLC | A randomized, evaluator-blinded, parallel group, comparator-controlled, multicenter study to evaluate the safety and effectiveness and safety of GP0112 for cheek augmentation, midface volumization and correction of midface contour deficiencies | No dispute reported | 06/30/2026 | 1234514686 |
| Principal investigator 1 | ABBVIE INC. | $1,466.60 | 05/07/2025 | Non-covered Recipient Entity INVESTIGATE MD LLC | A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) | No dispute reported | 06/30/2026 | 1202483993 |
| Principal investigator 1 | ABBVIE INC. | $1,198.40 | 05/06/2025 | Non-covered Recipient Entity INVESTIGATE MD LLC | A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1202482229 |
| Principal investigator 1 | ABBVIE INC. | $1,198.40 | 04/03/2025 | Non-covered Recipient Entity INVESTIGATE MD LLC | A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1202470133 |
| Principal investigator 1 | Galderma Laboratories, L.P. | $23,909.62 | 03/31/2025 | Non-covered Recipient Entity INVESTIGATE MD LLC | A randomized, evaluator-blinded, parallel group, comparator-controlled, multicenter study to evaluate the safety and effectiveness and safety of GP0112 for cheek augmentation, midface volumization and correction of midface contour deficiencies | No dispute reported | 06/30/2026 | 1234513991 |
| Principal investigator 1 | ABBVIE INC. | $2,881.90 | 03/07/2025 | Non-covered Recipient Entity INVESTIGATE MD LLC | M24-541 - A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) | No dispute reported | 06/30/2026 | 1202461298 |
| Principal investigator 1 | Galderma Laboratories, L.P. | $7,066.12 | 03/03/2025 | Non-covered Recipient Entity INVESTIGATE MD LLC | A randomized, evaluator-blinded, parallel group, comparator-controlled, multicenter study to evaluate the safety and effectiveness and safety of GP0112 for cheek augmentation, midface volumization and correction of midface contour deficiencies | No dispute reported | 06/30/2026 | 1234513519 |
| Principal investigator 1 | Galderma Laboratories, L.P. | $1,582.86 | 02/14/2025 | Non-covered Recipient Entity INVESTIGATE MD LLC | A randomized, evaluator-blinded, parallel group, comparator-controlled, multicenter study to evaluate the safety and effectiveness and safety of GP0112 for cheek augmentation, midface volumization and correction of midface contour deficiencies | No dispute reported | 06/30/2026 | 1234513278 |
| Principal investigator 1 | ABBVIE INC. | $305.70 | 02/05/2025 | Non-covered Recipient Entity INVESTIGATE MD LLC | M16-047 - A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1202444463 |
| Principal investigator 1 | Eli Lilly and Company | $6,754.95 | 01/15/2025 | Non-covered Recipient Entity INVESTIGATE MD, LLC | A PHASE 3, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED TRIAL TO EVALUATE THE EFFICACY, SAFETY, AND PHARMACOKINETICS (PK) OF BARICITINIB IN CHILDREN FROM 6 YEARS TO LESS THAN 18 YEARS OF AGE WITH ALOPECIA AREATA | No dispute reported | 06/30/2026 | 1187882184 |
| Principal investigator 1 | ABBVIE INC. | $389.70 | 01/02/2025 | Non-covered Recipient Entity INVESTIGATE MD LLC | M16-047 - A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1202434121 |
| Principal investigator 1 | ABBVIE INC. | $1,415.30 | 01/02/2025 | Non-covered Recipient Entity INVESTIGATE MD LLC | M24-541 - A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) | No dispute reported | 06/30/2026 | 1202434125 |